AUTHOR=Zhong An-Ni , Yin Yi , Tang Bing-Jie , Chen Lei , Shen Hong-Wei , Tan Zhi-Ping , Li Wen-Qun , He Qun , Sun Bao , Zhu Yan , Xiao Jie , Jiang Zhi-Ping , Xu Ping 

TITLE=CircRNA Microarray Profiling Reveals hsa_circ_0058493 as a Novel Biomarker for Imatinib-Resistant CML

JOURNAL=Frontiers in Pharmacology

VOLUME=Volume 12 - 2021

YEAR=2021

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.728916

DOI=10.3389/fphar.2021.728916

ISSN=1663-9812

ABSTRACT=Background: CircRNA has appeared as a critical molecular in the development of various cancers. However, the cellular function of circRNAs and exosomal circRNAs has not been well explored in CML. 
Methods: Differentially expressed circRNAs were identified by a human circRNA microarray analysis. The expression of hsa_circ_0058493 in monocytes and exosomes was verified using quantitative real-time PCR. Short hairpin RNAs against hsa_circ_0058493 were constructed to silence the expression of circ_0058493. CCK8, flow cytometry and EdU assay were performed to investigate the biological functions of circ_0058493.
Results: Hsa_circ_0058493 was significantly overexpressed in the monocytes of CML patients and high level of circ_0058493 was associated with the poor clinical efficacy of imatinib. Silencing the expression of circ_0058493 significantly inhibited the development of imatinib-resistant CML cells. miR-548b-3p was overexpressed in circ_0058493-downregulated CML cells. Bioinformatic analysis revealed that circ_0058493 might exert its regulatory function acting as a “sponge” of miR-548b-3p. Moreover, hsa_circ_0058493 was significantly enriched in the exosomes derived from imatinib-resistant CML cells.
Conclusion: Hsa_circ_0058493 is a promising biomarker for CML prognosis and may provide a therapeutic target for CML treatment.